| Pharmaceutical Information |
| Drug Name |
Taliglucerase alfa |
| Drug ID |
BADD_D02110 |
| Description |
Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease. |
| Indications and Usage |
For the treatment of adult Type 1 Gaucher disease. |
| Marketing Status |
Prescription |
| ATC Code |
A16AB11 |
| DrugBank ID |
DB08876
|
| KEGG ID |
D09675
|
| MeSH ID |
C582473
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0G6HA
|
| NDC Product Code |
0069-0106; 0009-0106 |
| Synonyms |
taliglucerase alfa | elelyso |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
37228-64-1 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
